Genprex, Inc. — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
Genprex is a clinical-stage gene therapy company developing REQORSA Immunogene Therapy for lung cancer and GPX-002/GPX-003 programs for Type 1 and Type 2 diabetes. The filing covers the three and six months ended June 30, 2023. The interim financial statements are unaudited.
Financial Performance and Liquidity
| Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $4.0 million | $2.9 million | $9.3 million | $5.0 million |
| General and administrative expense | $4.1 million | $2.8 million | $8.0 million | $6.1 million |
| Total operating expenses | $8.0 million | $5.8 million | $17.3 million | $11.1 million |
| Net loss | $8.0 million | $5.8 million | $17.2 million | $11.1 million |
| Net loss per share | $0.15 | $0.12 | $0.34 | $0.23 |
| Cash used in operating activities | Not separately provided | Not separately provided | $15.0 million | $8.6 million |
Cash and cash equivalents were $10.0 million at June 30, 2023, compared with $21.0 million at December 31, 2022. Current liabilities were $3.9 million and stockholders’ equity was $12.1 million. The company had no debt balance identified in the filing, but reported substantial recurring losses and an accumulated deficit of $120.0 million.
Cash declined by $11.0 million during the first six months of 2023. Financing activities provided $4.1 million, primarily from the March registered direct offering and ATM sales. The company states that, including approximately $6.7 million of net proceeds from a July 2023 offering, existing funds are expected to support necessary operations and planned clinical activities into the third quarter of 2024, subject to assumptions and spending rates.
Material Changes Versus the Prior Comparable Period
- Six-month R&D expense increased 87% to $9.3 million, driven by clinical trial activity, manufacturing and CDMO costs, sponsored research, and higher personnel levels.
- Six-month G&A expense increased 31% to $8.0 million, reflecting increased personnel, consultants, professional services, legal fees, and share-based compensation.
- Six-month net loss increased 55% to $17.2 million, while operating cash use increased 76% to $15.0 million.
- Headcount increased from 21 employees at June 30, 2022 to 30 employees at June 30, 2023.
- Common shares outstanding increased from 48.1 million at December 31, 2022 to 52.0 million at June 30, 2023, excluding subsequent July issuance. Warrants outstanding totaled 5.9 million at June 30, 2023.
Guidance, Outlook, Risks, and Unusual Items
- Acclaim-1 completed Phase 1 dose escalation with no dose-limiting toxicities reported by the Safety Review Committee. The recommended Phase 2 dose is 0.12 mg/kg, and first-patient dosing in the Phase 2 expansion is expected in the fourth quarter of 2023.
- Acclaim-2 is enrolling patients in Phase 1 dose escalation. Enrollment is expected to be completed in the second quarter of 2024, subject to trial execution and regulatory or committee decisions.
- First-patient dosing for Acclaim-3 is expected in the fourth quarter of 2023.
- Production of a new REQORSA batch has been delayed during the transition to an LNP contract development and manufacturing organization. Existing supply is expected to support ongoing trials through approximately October 2023. Further delays could interrupt treatment and postpone Acclaim-1 and Acclaim-3 dosing.
- The company has no current product revenue and expects continuing substantial R&D expenditures. Management states that additional financing will be required and that substantial doubt exists regarding the company’s ability to continue as a going concern.
- On July 21, 2023, Genprex sold 7.4 million shares and warrants for approximately $6.7 million of net proceeds. The transaction also created substantial potential dilution through warrants exercisable for up to 7.9 million shares, including placement-agent warrants.
- The FDA granted Fast Track Designation for the Acclaim-3 combination in June 2023; Orphan Drug Designation for REQORSA in SCLC was granted in August 2023.
- Disclosure controls and procedures were not effective as of June 30, 2023 because of material weaknesses involving segregation of duties and insufficient accounting personnel with expertise in complex transactions. Management reported remediation efforts but stated that the weaknesses had not yet been remediated.
- Key risks include the ability to raise capital, clinical and regulatory failure, manufacturing scale-up and supply interruptions, trial enrollment delays, reliance on third-party manufacturers and research partners, intellectual-property protection, dilution, and uncertainty regarding commercialization.
Important Facts for Investors to Verify
- Confirm the company’s post-June 30 cash balance, cash burn rate, and whether the stated runway into the third quarter of 2024 remains achievable.
- Monitor production of the new REQORSA batch and any resulting effect on Acclaim-1 and Acclaim-3 timelines.
- Track Acclaim-1 Phase 2 initiation, Acclaim-2 enrollment, and Acclaim-3 first-patient dosing.
- Assess future financing needs, ATM usage, warrant exercises, and the resulting dilution.
- Review the status and effectiveness of remediation efforts for the disclosed material weaknesses in internal controls.
- Verify clinical efficacy and safety data independently; the filing’s favorable platform and preclinical statements do not establish regulatory approval or commercial success.